194 related articles for article (PubMed ID: 11772323)
1. Advances in the non-surgical treatment of melanoma.
Hersey P
Expert Opin Investig Drugs; 2002 Jan; 11(1):75-85. PubMed ID: 11772323
[TBL] [Abstract][Full Text] [Related]
2. Melanoma vaccines: achievements and perspectives.
Brichard VG; Gérard C
Forum (Genova); 2003; 13(2):144-54; quiz 189. PubMed ID: 14732881
[TBL] [Abstract][Full Text] [Related]
3. Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma.
Schadendorf D; Paschen A; Sun Y
Immunol Lett; 2000 Sep; 74(1):67-74. PubMed ID: 10996630
[TBL] [Abstract][Full Text] [Related]
4. [Vaccine strategies against melanoma].
Ghiringhelli F; Zitvogel L
Med Sci (Paris); 2006 Feb; 22(2):183-7. PubMed ID: 16457760
[TBL] [Abstract][Full Text] [Related]
5. T-cell-based immunotherapy of melanoma: what have we learned and how can we improve?
Campoli M; Ferrone S
Expert Rev Vaccines; 2004 Apr; 3(2):171-87. PubMed ID: 15056043
[TBL] [Abstract][Full Text] [Related]
6. Melanoma vaccines.
Minev BR
Semin Oncol; 2002 Oct; 29(5):479-93. PubMed ID: 12407513
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of Melanoma.
Snyder A; Zamarin D; Wolchok JD
Prog Tumor Res; 2015; 42():22-9. PubMed ID: 26376963
[TBL] [Abstract][Full Text] [Related]
8. Tumor vaccines: a role in preventing recurrence in melanoma?
Sabel MS; Sondak VK
Am J Clin Dermatol; 2002; 3(9):609-16. PubMed ID: 12444803
[TBL] [Abstract][Full Text] [Related]
9. Immunity to melanoma antigens: from self-tolerance to immunotherapy.
Slingluff CL; Chianese-Bullock KA; Bullock TN; Grosh WW; Mullins DW; Nichols L; Olson W; Petroni G; Smolkin M; Engelhard VH
Adv Immunol; 2006; 90():243-95. PubMed ID: 16730266
[TBL] [Abstract][Full Text] [Related]
10. Vaccine Strategy in Melanoma.
Kwak M; Leick KM; Melssen MM; Slingluff CL
Surg Oncol Clin N Am; 2019 Jul; 28(3):337-351. PubMed ID: 31079792
[TBL] [Abstract][Full Text] [Related]
11. Recent advances and hurdles in melanoma immunotherapy.
Jandus C; Speiser D; Romero P
Pigment Cell Melanoma Res; 2009 Dec; 22(6):711-23. PubMed ID: 19735459
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for melanoma.
Komenaka I; Hoerig H; Kaufman HL
Clin Dermatol; 2004; 22(3):251-65. PubMed ID: 15262312
[TBL] [Abstract][Full Text] [Related]
13. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine.
Hsueh EC; Morton DL
Semin Cancer Biol; 2003 Dec; 13(6):401-7. PubMed ID: 15001158
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of malignant melanoma.
Kadison AS; Morton DL
Surg Clin North Am; 2003 Apr; 83(2):343-70. PubMed ID: 12744613
[TBL] [Abstract][Full Text] [Related]
15. Review: dendritic cell immunotherapy for melanoma.
Hadzantonis M; O'Neill H
Cancer Biother Radiopharm; 1999 Feb; 14(1):11-22. PubMed ID: 10850282
[TBL] [Abstract][Full Text] [Related]
16. Active immunotherapy with allogeneic tumor cell vaccines: present status.
Chan AD; Morton DL
Semin Oncol; 1998 Dec; 25(6):611-22. PubMed ID: 9865676
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of melanoma.
Hersey P
Asia Pac J Clin Oncol; 2010 Mar; 6 Suppl 1():S2-8. PubMed ID: 20482529
[TBL] [Abstract][Full Text] [Related]
18. [Gene modified tumor vaccines in therapy of malignant melanoma].
Wysocki PJ; Karczewska A; Mackiewicz A
Otolaryngol Pol; 2002; 56(2):147-53. PubMed ID: 12094637
[TBL] [Abstract][Full Text] [Related]
19. Current status and future prospects for adjuvant therapy of melanoma.
Hersey P; Balch CM
Aust N Z J Surg; 1984 Aug; 54(4):303-15. PubMed ID: 6207805
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
